Cachexia and advanced dementia by Minaglia, C. et al.
Cachexia and advanced dementia
Cecilia Minaglia1, Chiara Giannotti1, Virginia Boccardi2, Patrizia Mecocci2, Gianluca Seraﬁni3,4, Patrizio Odetti1,5 &
Fiammetta Monacelli1,5*
1Department of Internal Medicine and Medical Specialties (DIMI), Section of Geriatrics, University of Genoa, Genoa, Italy, 2Department of Medicine, Institute of Gerontology
and Geriatrics, University of Perugia, Perugia, Italy, 3Department of Neuroscience, Rehabilitation, Ophthalmology, Genetics, Maternal and Child Health, University of Genoa,
Genoa, Italy, 4Section of Psychiatry, I.R.C.C.S. Ospedale Policlinico San Martino, Genoa, Italy, 5IRCCS Ospedale Policlinico San Martino, Genoa, Italy
Abstract
Cachexia is a complex metabolic process that is associated with several end-stage organ diseases. It is known to be also asso-
ciated with advanced dementia, although the pathophysiologic mechanisms are still largely unknown. The present narrative
review is aimed at presenting recent insights concerning the pathophysiology of weight loss and wasting syndrome in demen-
tia, the putative mechanisms involved in the dysregulation of energy balance, and the interplay among the chronic clinical con-
ditions of sarcopenia, malnutrition, and frailty in the elderly. We discuss the clinical implications of these new insights, with
particular attention to the challenging question of nutritional needs in advanced dementia and the utility of tube feeding in
order to optimize the management of end-stage dementia.
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Introduction
Cachexia is a complex metabolic process associated with
underlying terminal illnesses including end-stage renal
disease, cancer, advanced heart and lung failure, and
others. It is mainly characterized by anorexia and loss of
fat and muscle mass.1 Approximately 10–40% of patients
with chronic diseases, including heart failure, chronic ob-
structive pulmonary disease, cancer, human immunodeﬁ-
ciency virus, and renal and hepatic failure become
cachexic. However, reliable estimates for the incidence of
cachexia in the elderly are not available. The interplay be-
tween sarcopenia, malnutrition, and inactivity, which show
increasing prevalence with ageing, makes this group partic-
ularly vulnerable to cachexia.2
Cachexia usually presents as severe wasting, and it is
frequently associated with insulin resistance (IR), myolysis,
and systemic inﬂammation. The Special Interest Group on
cachexia–anorexia in chronic wasting diseases of the Euro-
pean Society for Clinical Nutrition and Metabolism recently
proposed a consensus deﬁnition to differentiate between
cachexia and sarcopenia.3 Accordingly, a diagnosis of ca-
chexia is based on a set of core criteria,3 namely, the
presence of an underlying chronic disease, an uninten-
tional weight loss of >5% of the usual body weight during
the last 6 months, and anorexia or anorexia-related
symptoms.
Cachexia is viewed as a multifactorial syndrome that is
characterized by an acute loss of body weight (fat and muscle
mass) and increased protein catabolism in the setting of an
underlying disease. Cachexia increases morbidity and mortal-
ity, and as such, it is a highly relevant clinical condition. Major
contributors to cachexia include systemic inﬂammation, in-
creased muscle proteolysis, and impaired carbohydrate, pro-
tein, and lipid metabolism.3
Taking this as the current scientiﬁc background, the pres-
ent narrative review is aimed at assessing the impact of ca-
chexia in advanced dementia. A literature search in
PubMed, Medline, and the Cochrane databases of all arti-
cles published with the medical subject heading keywords
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‘aging’, ‘dementia’, ‘Alzheimer’s disease’, ‘cachexia’,
‘sarcopenia’, ‘older adults’, ‘frailty’, ‘nutrition’, and ‘an-
orexia of ageing’ was carried out. The keywords were
matched in all of the potential combinations, and all types
of studies, from bench and animal models to the clinical
ﬁeld, were included. The review provides an overview of
the anorexia of ageing, sarcopenia, frailty, and cachexia in
older adults and their clinical interplay.
In particular, the evidence from bench to bedside on the
cachexia of advanced dementia is provided, with a focus on
the pathophysiology and underlying molecular mechanisms.
The review concludes with a discussion of the nutritional
needs of elderly patients with advanced dementia, including
implications and challenges for future research.
Anorexia of ageing
One of the core characteristics of cachexia is the presence of
anorexia. The anorexia of ageing, namely, the loss of appetite
and decreased food intake later in life, was ﬁrst recognized as
a physiological syndrome more than 30 years ago, framing a
key paradigm for geriatric syndromes. From this, the major
cause of the anorexia of ageing lies on an alteration in fundal
compliance, with an increase in antral stretch and enhanced
cholecystokinin activity, leading to early satiety. It is further
hypothesized that the anorexia of ageing arises from
inﬂammation-driven losses of appropriate hypothalamic re-
sponses to orexigenic and anorexigenic signals. The mecha-
nisms that are involved in age-related changes in the
speciﬁc activities of brain areas such as the hypothalamus in
response to peripheral stimuli including nutrients, hormones,
and adipokines are complex.4 Reduced appetite and a de-
creased total energy expenditure are common in older indi-
viduals, but the frail elderly and those with chronic co-
morbidities often show an increased basal metabolism. Re-
duced total energy expenditure, along with biological and
physiological changes (reduced lean body mass, changes in
hormonal proﬁles, ﬂuid–electrolyte dysregulation, delayed
gastric emptying, and diminished sense of smell and taste),
lead to the anorexia of ageing.5 In addition, multiple morbid-
ities, polypharmacy, and social and psychological vulnerabil-
ities all play a role in the complex aetiology of anorexia and
in the subsequent onset of malnutrition in the elderly. The
physiological anorexia of ageing places the older person at in-
creased risk of weight loss and wasting syndrome when an
acute illness intervenes. Indeed, the pro-inﬂammatory
cytokine burst usually accompanies the onset of an acute
illness, and it has been associated with the risk of a sudden
worsening of age-related anorexia.5 In turn, the physiologic
anorexia of ageing that increases the risk of sudden weight
loss and malnutrition in the presence of a physical or
psychological illness may also precipitate sarcopenia.6 The
development of the anorexia of ageing is inﬂuenced by co-
morbidity and directly interferes with nutritional status and
favours malnourishment.5–9 Functional impairment, social
and environmental factors, and polypharmacy represent only
some of the risk factors associated with age-related weight
loss.8
Notwithstanding the evidence so far, the interplay among
anorexia, sarcopenia, and cachexia remains only partly under-
stood, especially in the highly vulnerable elderly population,5
representing an ongoing research challenge.
Sarcopenia
It is noteworthy that cachexic older adults are co-morbid for
sarcopenia, but those who are sarcopenic are rarely co-morbid
for cachexia. Sarcopenia is a core characteristic of the pro-
posed deﬁnition for cachexia,10 and sarcopenia and cachexia
are two major markers of malnutrition in older adults.
Sarcopenia has been reported to affect 5–13% of persons aged
60 to 70 years and up to 50% of those aged over 80 years.11,12
Reduced muscle mass, tone, and strength in the elderly are in-
dependently associated with increased risk of functional im-
pairment, falls, disability, decreased physical performance,
poorer quality of life, and mortality.13 In the year 2000, costs
attributed directly to sarcopenia accounted for 1.5% of the to-
tal healthcare expenditure, and it is estimated that a 10% re-
duction in the prevalence of sarcopenia would save 1.1
billion dollars in health-related costs.14
Frailty and cachexia
Frailty in the geriatric patient is a syndrome resulting from cu-
mulative age-related declines across multiple physiologic sys-
tems, with impaired homeostatic reserve and a diminished
ability to withstand environmental stressors. This syndrome
is associated with greater vulnerability to adverse health out-
comes such as falls, hospitalizations, institutionalization, and
mortality.
There are three main paradigms of frailty. Fried et al.15 em-
phasizes the physiologic view of frailty, deﬁning it as a physi-
ological syndrome characterized by the reduction of
functional reserves and a diminished resistance to stressors
due to the cumulative decline of multiple physiological sys-
tems, which causes vulnerability and adverse consequences.
According to Fried’s deﬁnition, the onset of frailty is heralded
by at least three of the following readily identiﬁable changes:
unintended weight loss, exhaustion, weakness, slow gait
speed, and reduced physical activity. There is a signiﬁcant
overlap between frailty and sarcopenia. In fact, most of the
frail elderly population is sarcopenic, which suggests a com-
mon pathogenic mechanism.
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The second theory of frailty supports the biopsychosocial
model proposed by Gobbens et al.16 which views frailty as a
dynamic state characterized by losses in any functional do-
main (physical, psychic, or social) that are ‘caused by the in-
ﬂuence of multiple variables that increase the risk of
adverse health outcomes’.
Finally, Rockwood et al.17 has proposed an alternative def-
inition of frailty, which is based on counting the number of
clinical deﬁcits accumulated over time. This theory also views
frailty as a dynamic condition that is caused by a loss of phys-
iological systems complexity, reﬂected by the functional
state, diseases, cognitive deﬁcits, psychosocial risk factors,
and geriatric syndromes, including malnutrition and
sarcopenia According to the Rockwood frailty index, the
frailty trajectory is a continuum that ends with a failure to
thrive that mainly resembles cachexia.
Again, the conceptual framework of frailty in the elderly
views sarcopenia and malnutrition as the main drivers for
the acceleration of frailty, with cachexia as the end-stage sta-
tus (Figure 1).
In line with these assumptions, the general concept of
frailty goes beyond physical factors to encompass
psychological and social dimensions as well. This may
include cognitive decline and dementia as core features of
frailty, which signiﬁcantly shape its clinical trajectory over
time.
The main core features of these intertwined clinical enti-
ties are illustrated in Table 1.
Cachexia and dementia
It is noteworthy that scant data are available on the role of
sarcopenia in dementia and that even fewer studies are fo-
cused on the link between cachexia and dementia, especially
in its advanced stages.18 This putative association becomes
particularly relevant in light of the anticipated global increase
in the incidence of dementia, with up to nine million new cases
of Alzheimer’s disease (AD) projected by the year 2040. The es-
timated prevalence of severe dementia among individuals
older than 85 (the oldest old) is much higher, ranging from
25 to 45%.19 Alzheimer’s dementia is a progressive degenera-
tive disorder that leads to an eventual loss of independence,
and it is one of the leading causes of death in the elderly.20
The natural history of dementia spans over 10 years, and the
later stages of the disease are marked by substantial uninten-
tional weight loss, malnutrition, sarcopenia, anorexia, lethargy,
altered immune function, and cachexia.21
It is well known that patients with dementia develop nutri-
tional disorders early and over the course of their disease.
The National Institute of Neurological and Communicative
Disorders and Strokes Task Force on AD includes weight loss
Figure 1 The interplay between anorexia/malnutrition, sarcopenia, cachexia, and dementia. AGEs, advanced glycation end products; IL, interleukin;
TNF-alpha, tumour necrosis factor alpha.
Cachexia in dementia 265
Journal of Cachexia, Sarcopenia and Muscle 2019; 10: 263–277
DOI: 10.1002/jcsm.12380
among the clinical features that are consistent with a diagno-
sis of AD.22 This weight loss is a multifactorial event, related
not only to the cognitive impairment that is associated with
loss of appetite and reduced food intake but also to AD-linked
alterations of energy consumption due to hypothalamic feed-
ing dysregulation, olfactory changes and psycho-behavioural
disturbances, and the dysphagia (apraxia of swallowing) that
is a common feature in the later stages of the disease, and
which may also worsen malnutrition.23
Loss of body weight in AD is also typically associated with
sarcopenia, which leads to further functional decline, greater
disability, and increased clinical vulnerability, and perpetu-
ates the cycle of altered food consumption and decreased en-
ergy intake.
While it is still argued that the weight loss associated with
AD may be entirely prevented by counteracting all of these
predisposing causes, there is also strong evidence that weight
loss is probably a true manifestation of the disease itself.
Although epidemiological evidence suggests that middle-
aged individuals with obesity are at a higher risk of develop-
ing dementia, older adults seem to display a more likely asso-
ciation between weight loss and dementia. The physiological
weight loss that accompanies ageing is exaggerated in older
patients with AD, even years before the cognitive decline sets
in.24 Moreover, weight loss seems to progress according to
the natural history of the disease, leading to failure to thrive
in the advanced stages with common features that resemble
cachexia.25
Unintentional weight loss may in fact be a harbinger of AD,
appearing before the detectable clinical onset of dementia.
Although the association between early weight loss and de-
mentia is still far from being understood, it is known that pa-
tients with AD sometimes exhibit a paradoxical pattern of
overeating concomitant with weight loss.26 This pattern
may suggest a hypermetabolic state,27,28 although it is un-
known whether metabolic abnormalities occur in patients
with AD, because no signiﬁcant changes in basal metabolism
have yet been observed in association with the disease.29,30
From the clinical point of view, there are several behav-
iours that are commonly associated with Alzheimer’s demen-
tia that could contribute to daily metabolic disturbances,
including wandering, increased physical activity, and
sundowning with circadian disturbances, all of which involve
increased energy expenditure.31–34
The unexplained weight loss and low body mass index that
have been associated with AD may also be linked to an in-
crease in the resting metabolic rate.35 This ﬁnding supports
the theory that central regulators of body composition and
energy balance, such as hypothalamic control of adipose me-
tabolism, are altered in AD.
Further research suggests that body composition may in-
ﬂuence AD-associated energy demands. To test this hypothe-
sis, the resting metabolic state that counts for a large part of
the daily energy expenditure for the maintenance of homeo-
stasis has been investigated.30
The debate continues over whether the wasting syndrome
is a prodromal symptom of dementia or whether it appears
during the intermediate stages of the disease, driving
sarcopenia to cachexia in the late stages of an irreversible fail-
ure to thrive.
In line with that, whether cachexia may represent the ﬁrst
clinical symptom of dementia or a mere side symptom along
with its natural history is still far from being understood. So
far, further studies with regard to these questions are war-
ranted to implement this conceptual framework.
However, so far, in the advanced stages of dementia, the




It has been suggested that neuroinﬂammation contributes to
the wasting syndrome in dementia, leading to cachexia.36,37
Appetite-controlling metabolites and adipokines have been
implicated in this pathophysiology. Alterations in plasma
levels of leptin and tumour necrosis factor alpha (TNF-α) are
prominent anorexic signals in patients with AD, as supported
by the ﬁnding of a female gender dimorphism in the levels of








Cachexia Unintentional weight loss of >5%
of the usual body weight during the last 6 months
+++ +++ +++





Loss of appetite and decreased food intake later in life +++ +/ +/
Frailty
syndrome
Multisystem syndrome of low physiological
reserves, with a diminished capacity to respond to stressors
++ ++ ++
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circulating anorectic adipokines in AD patients.38 Pro-
inﬂammatory cytokines are known to mimic appetite-
regulating peptides and to suppress glucose-sensitive neu-
rons. Leptin and TNF-α have been mostly implicated in this
immunological hypothesis, linking AD and anorexia–cachexia.
Nonetheless, the role of these adipokines and their patho-
physiological contribution to cachexia remains only partially
elucidated.
AD has also been deﬁned as an eating disorder, and the
role of several appetite-controlling metabolites has been in-
vestigated. A few in vivo models, particularly regarding the
cachexia of dementia, have provided evidence of the meta-
bolic consequences of β-amyloid-induced dementia.
Namely, experiments in rat models have demonstrated
that the injection of β-amyloid into the hippocampus induces
metabolic disturbances and involuntary weight loss, both of
which are early potential indicators of AD.39
Several models of amyloid deposition in AD have described
reduced body weight and increasing feeding behav-
iour.27,28,40 Speciﬁcally, Tg 2576 amyloid precursor protein
mice have exhibited weight reduction and increased energy
expenditure, without any perturbation of feeding
behaviour.41,42
In addition, abnormalities in circadian rhythms were ob-
served in the same murine model, combined with decreased
body weight, hyperactivity, and increased agitation.43–46
In keeping with that, the previous results39 expanded this
research. In fact, β-amyloid injection into the hippocampus
induced immediate morphological alterations and weight loss
after 3 weeks in both diabetic and non-diabetic rats, and, in-
terestingly, visceral fat was preserved at the expense of lean
mass. These reports are consistent with the hypothalamic-
mediated cachexia that causes loss of appetite, anorexia, in-
voluntary weight loss, and lethargy in patients with advanced
dementia.
The mouse model of tau protein accumulation in AD has
also advanced the understanding of cachexia in advanced de-
mentia. Hyperactivity, increased agitation, and decreased
body weight have all been observed in animal models of
tau deposition, including THY-22 (P301S mutation under a
Thy1.2 promotor) and Tg4510 mice.47,48
Further evidence shows that transgenic mice overexpress-
ing the tau protein seemed to eat more yet weighed less than
their non-transgenic littermates.
In addition, this recent in vivo model measured the time
course of changes in the metabolic state over the lifespan
of the tau-depositing Tg4510 mice. Interestingly, the mice
weighed less at older ages, and this was paralleled by the
pathologic accumulation of tau and by dramatic increases in
physical activity.
A wasting phase began at 12 months, near the end of the
Tg4510 mouse lifespan, with a considerable decrease in the
resting metabolic rate, although hyperactivity and food intake
were maintained. Hyperphosphorylated tau was detected in
the hypothalamus at both 7 and 10 months, which may have
contributed to the variation in energy expenditure, food efﬁ-
ciency, and body weight.
Furthermore, the volume of adipose tissue and the plasma
leptin levels were signiﬁcantly decreased in aged mice, indi-
cating a dysregulation of the hypothalamic adipostat control
mechanism and energy storage. This last ﬁnding is in line with
the results of Ishii et al.,42 who reported that amyloid precur-
sor protein Tg2576 mice showed hypothalamic leptin signal-
ling dysfunction, leading to body weight deﬁcits. The
observations seem to correlate to the dysfunctional
orexigenic effects of neuropeptide Y in the hypothalamus.
Originally, in the THY-Tau mouse model, a reduction of se-
rotoninergic neurons was observed,22 possibly being involved
in the reduction of serotonin (5HT) as an anorexic
neurotransmitter.48
It is noteworthy that the Tg4510 model of tauopathy
depicted a biphasic energy metabolism response. In particu-
lar, the phenotype observed in those mice aged 12 months
bears some resemblance to the symptoms of cachexia.
These recent ﬁndings support a key relevance of tau in
weight loss and metabolic dysregulation, especially in light
of the hypothesis that hypermetabolism is responsible for
weight loss in AD.
The in vivo tauopathy model of AD showed that a progres-
sively hyperactive phenotype with an increased metabolic
rate was not adequately compensated by increased food in-
take in 7-month-old mice. As these mice reached the end of
their lifespan (average longevity is 11.5months), the hyperac-
tivity persisted, but it was ultimately compensated by a re-
duced resting metabolic rate, despite lower energy intake,
at 12 months of age.
These animal models of cachexia-related metabolic distur-
bances and dysregulated metabolic homeostasis could add
knowledge to the understanding of both cognitive deﬁcit
and muscle wasting syndrome in dementia, until its ﬁnal
stages.
Insulin and glucose homeostasis
The pathophysiology of the wasting syndrome in dementia is
even more poorly understood. It is known that AD is associ-
ated with impaired glucose signalling, which is a key risk fac-
tor for diabetes, and some have proposed that AD should be
considered type 3 diabetes. The progressive onset of IR that
occurs with ageing is a result of the progressive metabolic re-
modelling that characterizes the ageing process. It affects an-
thropometric, endocrine, and metabolic parameters, and it is
manifested by the aberrant regulation of glucose and protein
metabolism.49,50
However, the evidence consistently supports the hypothe-
sis that the IR of ageing is not simply a routine metabolic ﬁnd-
ing. Rather, it may also be a major risk factor for many age-
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related diseases. Age-related IR is widely known to be associ-
ated with altered lipid metabolism, impaired endothelial
function, pro-thrombotic status, and increased inﬂammatory
response, and it is also involved in the regulatory functions
of the brain.
Reductions in glucose metabolism have been found in the
hippocampus of AD patients, and intravenous insulin infusion
to maintain normal plasma glucose levels can improve cogni-
tive function in both AD patients and in cognitively healthy
volunteers. This ﬁnding reliably indicates that normal glucose
metabolism is required for optimal cognitive performance,
and the achievement and maintenance of good glycaemic
control may be the most important way to prevent the onset
and progression of cognitive decline in diabetes.
The pathophysiologic impact of diabetes in cognitive im-
pairment has not been completely elucidated, and the impact
of diabetes on the brain, particularly in relation to cognitive
decline, is still under investigation. IR, hyperinsulinaemia,
hyperglycaemia, hypoglycaemia, neuroinﬂammation, and
vascular disease certainly play a role. Oxidative stress, ad-
vanced glycation products, and impaired insulin signalling in
the brain also underlie the association between diabetes
and cognitive dysfunction.
Insulin is able to cross the blood–brain barrier and exerts
its effects by binding to a speciﬁc receptor, which is distrib-
uted throughout the brain (mainly in the hippocampus and
the cortex), and although its role in the brain is not fully un-
derstood,51–53 insulin is known to be not only a regulator of
energy homoeostasis and food intake but also a modulator
of brain activities such as learning and memory, mainly
through its inﬂuence upon the release and reuptake of other
neurotransmitters. Accordingly, patients with AD were found
to have lower cerebrospinal ﬂuid insulin levels.54,55
Type 2 diabetes is also associated with cognitive impair-
ment, but as mentioned previously, it is characterized by
hyperinsulinaemia and IR. Insulin is neurotrophic at moderate
concentrations. However, high levels of insulin in the brain
are associated with reduced β-amyloid clearance.55,56 This is
because insulin-degrading enzyme (IDE) is required for both
insulin and β-amyloid degradation in microglia and neurons.56
However, IDE is more selective for insulin than for β-amyloid.
Therefore, hyperinsulinaemia in type 2 diabetes essentially
deprives the brain of its main β-amyloid clearance mecha-
nism, leading to the inevitable accumulation of β-amyloid in
the brain and promoting many of the pathological changes
associated with AD.57
The accumulation of adiposity in the body that is charac-
teristic of clinical obesity is also linked to insulin dysregula-
tion, and an estimated 80% of obese patients will exhibit IR.
Insulin inhibits the action of lipase in adipocytes, which leads
to a decrease in the release of free fatty acids (FFAs) from the
adipose tissue. This process is compromised by IR, leading to
chronic elevations in plasma FFA levels, which promote neu-
roinﬂammation, induce the tissue accumulation of β-amyloid,
and inhibit β-amyloid clearance, all of which, as described
previously, are involved in the pathogenesis of cognitive
decline.57
Elevated concentrations of plasma FFA strongly and specif-
ically inhibit IDE, which plays a pivotal role in the modulation
of insulin signalling and β-amyloid clearance. Moreover, FFAs
also appear to be involved in the formation and accumulation
of amyloid and tau ﬁlaments in the brain tissue. FFAs directly
and indirectly activate the inﬂammatory response though in-
teractions with TNF-α and other pro-inﬂammatory cytokines
that are also involved in the pathogenesis of AD and, in turn,
are correlated with IR and hyperinsulinaemia.
There is also a direct correlation between adiposity and
blood leptin levels, which may be affected in conditions asso-
ciated with cognitive decline. Furthermore, a growing body of
evidence shows that leptin also has various effects on brain
health, cognition, and ageing. Accordingly, the discovery of
leptin receptors in the hippocampus, hypothalamus, amyg-
dala, and cerebellum strongly indicates the potential exis-
tence of regulatory mechanisms.57,58
Notwithstanding all of the molecular pathways involved in
the pathogenesis of AD, and the key ﬁndings concerning the
dual role of insulin in cognition and in the regulation of me-
tabolism, it is still largely unknown whether these same
mechanisms can also be implicated in the development of ca-
chexia associated with the later stages of neurodegeneration.
Mitochondrial dysfunction and oxidative stress
Age-related changes in redox homeostasis have been pro-
posed to play a role in sarcopenia and cachexia. However,
to date, the evidence for this comes mainly from the investi-
gation of cancer-related muscle wasting syndromes.59,60
In the broader conceptual framework, oxidative stress
causing increased levels of reactive oxygen species is among
the commonest mechanisms of cachexia. In particular, solu-
ble atrophic factors that are produced by various chronic dis-
eases induce an oxidative imbalance characterized by
increasing levels of oxidant species, such as O2, H2O2, and
OH, and decreasing levels of antioxidant species, such as cat-
alase, glutathione peroxidase, and superoxide dismutase. This
oxidative burst is mediated by the mitochondria as well as by
xanthine oxidase and NADPH oxidase complex. Oxidative
stress, in turn, increases oxidation-dependent protein modiﬁ-
cation, autophagy deregulation, myonuclear apoptosis, mito-
chondrial dysfunction, and ubiquitin proteasome and calpain
activity.61
Recent data obtained from experiments in knockout and
transgenic rodents seem to support a role for an unbalanced
mitochondrial redox environment in age-related mitochon-
drial dysfunction and impaired mitophagy, and it is now
thought that mitochondrial dysfunction also plays a role in
the loss of muscle in age- and cancer-related cachexia.62
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Namely, mitochondrial quality control derangements
targeting mitochondrial dynamics, mitochondrial tagging for
disposal, and mitophagy signalling are considered key check-
points for the development of cancer cachexia. Moreover,
dysfunctional mitochondrial quality control and neuroinﬂam-
mation have been considered to be at the crossroads of age-
ing and muscle wasting disorders. In particular, mitochondria-
derived damage-associated molecular patterns have been
speciﬁcally implicated in experimental sarcopenia and ca-
chexia models.63
However, our comprehensive literature search found that
the current body of evidence mainly concerns cachexia asso-
ciated with cancer, end-stage pulmonary disease, heart fail-
ure, and renal failure. Therefore, there is a knowledge gap
in regarding cachexia and dementia, and our understanding
of the pathophysiological background is currently based on
mere extrapolation from these other ﬁndings.
In summary, the study of the relationship between ca-
chexia and advanced dementia is in its infancy, and there
are persuasive arguments to support further investigation
of these unexplored signalling pathways.
From bench to bedside
Nutritional needs in advanced dementia
Cachexia is a hypercatabolic state, and, theoretically, nutri-
tional interventions containing 1.5 g/kg/day of protein should
be recommended to counteract catabolism.64
However, in line with both European Society for Clinical Nu-
trition and Metabolism65 and National Institute for Health and
Care Excellence guidelines,66 there is not sufﬁcient evidence to
support the use of dietary supplements to maintain the nutri-
tional status of patients with dementia. Enteral nutrition may
be useful in patients with mild to moderate dementia and re-
versible malnutrition, but neither guideline recommends the
use enteral nutrition in the terminal phase of dementia, al-
though the physician’s decision must ultimately rest on each
patient’s general prognosis and preferences.67
Conversely, the Japan Gastroenterological Endoscopy Soci-
ety has recommended percutaneous endoscopic gastrostomy
(PEG) placement in patients with malnutrition due to cere-
brovascular disease or dementia, with the assumption that
early PEG placement is associated with longer survival.68
The impact of tube feeding on mortality was equivalent for
patients with dementia, without dementia, or in those diag-
nosed with other neurological conditions, while patients with
dementia had decreased mortality compared with those with
strokes and increased mortality compared with those with tu-
mours. Trials of caloric supplementation or targeted protein
supplements, such as branched-chain amino acids or
creatine, have not shown consistent clinical beneﬁt for ca-
chexia prevention.69
As dementia progresses, it becomes increasingly difﬁcult to
maintain body weight through conventional feeding.70 Some
researchers have reported the beneﬁt of high-calorie supple-
mentation in more moderate stages of dementia, with clinical
improvement of nutritional indices including body mass in-
dex, arm circumference, arm muscle circumference, and total
lymphocyte count.71
However, nutritional interventions for patients with severe
dementia are inconsistent, and a series of biases such as co-
morbidity hamper the generalization of existing results.65,72
Although cachexia represents the ﬁnal stage of frailty and
dementia, it is systematically disregarded among cachexia-
related clinical conditions such as cancer or end-stage organ
failure.73
From a pathophysiological perspective, sarcopenia, frailty,
and dementia are largely mediated by a hypercatabolic and
inﬂammatory state, with deleterious effects on muscle mass
and brain, and while nutritional interventions in sarcopenia
resulted in fundamental therapeutic advantages, especially
in the earlier stages, nutritional interventions have demon-
strated minimal effect on cachexia in general, and there is
no evidence speciﬁc to cachexia associated with dementia.
Thus, cachexia might be considered a refractory symptom in
the clinical trajectory of dementia, culminating in the failure
to thrive, where the current deﬁnition of “refractory symp-
tom” is based on the palliative concept of resistance to
change-oriented stimuli.74 That is, it is a symptom that may
be not adequately controlled in spite of adequate and maxi-
mal therapy.
In line with these assumptions, Callahan75 has recom-
mended that in late-stage dementia, therapy and care should
be shifted towards end-of-life and palliative issues, in order to
maximize dignity and quality of life.76 Patients with advanced
dementia commonly experience burdensome symptoms such
as dyspnoea, pain, and agitation, similarly to patients who are
dying with cancer,77 with fewer tools for systematic
assessment.78
Artiﬁcial nutrition and advanced dementia
Dysphagia is a major risk factor for poor clinical outcomes, in-
cluding pneumonia, malnutrition, and cachexia. Dysphagia
secondary to advanced dementia is a progressive, irrevers-
ible, and incurable condition with a multifactorial pathogene-
sis that involves apraxia, cognitive ﬂuctuation, impulsivity,
reduced physical mobility, poor dentition, and dependence
for feeding and medications. Tube feeding [artiﬁcial nutrition
and hydration (ANH)] has been proposed as a means of pro-
tein and calorie supplementation for patients in the ﬁnal
stages of dementia to maintain skin integrity, prevent aspira-
tion pneumonia and other infectious complications, improve
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the functional status, and extend survival. ANH has been pop-
ularized as a caring and nurturing intervention, while forgoing
such measures has been equated with neglect and abandon-
ment.79 As such, the implementation of ANH in the advanced
stages of dementia has become a controversial and emo-
tional issue.
PEG tubes are routinely used for tube feeding in advanced
dementia patients with neurogenic dysphagia and cachexia,
and as many as 30% of all PEG tubes are placed in patients
with dementia.80 The current data on feeding tube placement
in patients with severe dementia (Table 1) are mainly retro-
spective in nature, with extrapolation from mixed popula-
tions, and to date, feeding tubes have shown little clinical
beneﬁt for the amelioration of malnutrition and the preven-
tion of pressure sores and aspiration pneumonia. Similarly,
no clinical beneﬁt has been observed for the improvement
of functional status, quality of care, and overall survival.
To the contrary, PEG placement is often burdensome, with
high rates of tube-related complications, including pain, su-
ture breakage, abdominal wall cellulitis and abscess, stoma
inﬂammation, bleeding, stenosis of the stoma, and
haematoma, as well as mechanical complications, including
erosions, tube leakage or blockage, tube migration and loose
ﬁxation plate, and tube malfunction due to a kinked or frac-
tured tube, which are frequently overlooked. Major complica-
tions, such as pleuro-pneumonitis, ileus, reﬂux, bowel
obstruction, anorexia, fever, sepsis, and ﬂuid overload and
metabolic disturbances, are also reported, and agitation,
self-extubation,81 abuse of physical restraints, and loss of
special aspects of food contribute to diminished well-being
and quality of life. The direct mortality from the placement
of a PEG tube is generally low, ranging from 0 to 2%, but
the complication rates may range from 15 to 70%.
Henderson et al. have found that that weight loss and se-
vere depletion of lean and fat body mass persisted in tube-
fed patients with advanced dementia even after a standard
enteral formula was provided daily for 1 year.82
Similarly, other studies have shown that nutritional markers
such as haemoglobin, haematocrit, albumin, and serum cho-
lesterol levels do not improve after a feeding tube is placed.83
It has also been demonstrated that weight loss progres-
sively worsened in parallel with the duration of the tube feed-
ing.84 This last ﬁnding seems to highlight the irreversible
progression of cachexia alongside the limitations and poten-
tially detrimental effects of ANH.
It seems that the scientiﬁc background turns out to be a
key determinant, supporting the need for future research
aimed at establishing the best clinical interventions according
to an updated pathophysiological conceptual framework.
Moreover, it has been reported that the incidence of
decubitus ulcers did not signiﬁcantly differ between patients
with dementia who had feeding tubes and those without
ANH.85–87 Similarly, Teno et al. observed a higher incidence
of new pressure ulcers, with poorer healing of existing ulcers,
in patients with advanced dementia who were tube fed, com-
pared with those without feeding tubes.88 These previous
studies also showed that feeding tubes did not reduce the
frequency of aspiration pneumonia in patients with advanced
dementia.85 In particular, a metanalysis compared the inci-
dence of aspiration between jejunostomy tubes and tradi-
tional PEG tubes with no additional clinical beneﬁts
between the two types.89
In addition, a retrospective study and several cohort nurs-
ing home studies have not shown any role for PEG feeding in
improving mental status, functional status, mobility, or over-
all survival over a period of 18 months,84,90 and the initiation
of tube feeding during hospitalization was also not associated
with increased survival.91–93
In contrast, few studies have reported no harm outcome
from tube feeding placement in patients with dementia, even
if retrospective in nature.94,95 Namely, Takenoshita et al. has
demonstrated that tube feeding decreased pneumonia and
antibiotic use in patients with advanced dementia, extending
survival rate as well.94 Similarly, enteral nutrition for patients
with dementia was reported to prolong survival. Additionally,
PEG tube feeding was observed to be safer than nasogastric
tube feeding among patients in psychiatric hospitals.95
These last ﬁndings do not necessarily indicate that tube
feeding should be administered in patients with severe de-
mentia. However, the scientiﬁc debate on which ethical deci-
sion should be formulated, when facing the nutritional issue
in advanced dementia and cachexia, should carefully consider
patient’s quality of life, before deciding the use or disuse of
tube feeding.
A 2009 Cochrane review of observational studies concluded
that there was insufﬁcient evidence to support the beneﬁts of
tube feeding in patients with advanced dementia in terms of
survival, quality of life, nutrition, functional status, prevention
of aspiration, or prevention and healing of pressure ulcers.96
Thus, feeding tubes do not appear to be a useful palliative
measure, and the use of ANH in end-stage dementia should
be generally discouraged, as it will only prolong the process
of dying and may also increase discomfort and suffering.
Although the line between cachexia and advanced demen-
tia is established along with the refractory nature of this clin-
ical entity, no speciﬁc research has been conducted on the
relationship between cachexia itself and any meaningful clin-
ical interventions (Table 2).
In summary, in line with these assumptions, no approved
treatment or recommendation for reversing cachexia and ad-
vanced dementia can be formulated at present.
End-of-life issues, advanced dementia, and
palliative care
Patients who survive to the ﬁnal phase of dementia are more
likely to die from cachexia, and the development of cachexia
270 C. Minaglia et al.
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is a common ﬁnal background that needs inclusion in a palli-
ative conceptual framework.67 The elaboration of grief, surro-
gate decision-making, and lack of effectiveness of nutrition
might magnify the caregiver’s burden,2 and the ﬁnal phase
of dementia unleashes an onslaught of emotions. Sorrow,
grief, fear, and anger may pervade the ﬁnal stages of this ter-
minal illness. However, our understanding of end-of-life is-
sues thus far is extrapolated from terminal illnesses other
than dementia.
The clinical course of advanced dementia has been de-
scribed in the Choices, Attitudes and Strategies for Care of
Advanced Dementia at the End of life (CASCADE) study, which
prospectively enrolled nursing home residents and showed a
median survival of 1.3 years, with the most common clinical
complications being eating problems (86%), febrile episodes
(53%), and pneumonia (41%).107,108
Similarly, the Study of Pathogen Resistance and Exposure
to Antimicrobials in Dementia (SPREAD) investigated nursing
home residents with advanced dementia, indicating that uri-
nary and respiratory tract infections were the main causes
for 1-year mortality.109
Approximately half of the patients with advanced demen-
tia receive a diagnosis of pneumonia in the last 2 weeks of
life, but palliative care needs may be overlooked in favour
of inappropriate use of antibiotics, representing dispropor-
tionate therapeutic aggressiveness.110
In a cohort study of nursing home residents with advanced
dementia, hospice care was provided for only 22.3% and
29.9% of those facing imminent death.111 The factors associ-
ated with greater likelihood of hospice referral were the pres-
ence of an eating problem and the perception by family
members that the resident had fewer than 6 months to live.
Those who received hospice services had fewer unmet needs
during the last week of life.112
These ﬁndings emphasize the need to improve end-of-life
care for elders with advanced dementia.
The application of palliative care principles to the natural
history of AD, and especially to its advanced stages, should
guide communication about treatment goals and family edu-
cation in order to avoid potentially futile and onerous clinical
interventions. The rate of hospice placement for end-stage
dementia has improved dramatically over the past two de-
cades,113 but end-of-life care in these patients remains a chal-
lenging issue.113
Lack of prognostic tools in advanced dementia may be a
key barrier to delivering hospice services and excellent end-
of-life care for these patients.114 Indeed, better prognostic
awareness among family members has been associated with
decreased use of burdensome interventions during the last
90 days of life among nursing home residents with advanced
dementia.115
The best practices for tailoring interventions and hospice
care expertise to the individual needs of patients with ad-
vanced dementia are far from being fully understood, but
up-to-date knowledge, forethought, and compassion allow
hospice providers and geriatric palliative care providers to en-
sure that patients with dementia will die with peace and
dignity.76
In terms of the strong need to reconcile the pan-culturally
symbolic act of feeding with dysphagia or refusal to eat and
cachexia in end-stage dementia, clinical observations have
conﬁrmed the beneﬁt of minimal interventions including
swabs, sips of water, ice chips, lubrication of the lips, and oral
comfort feeding.116 Oral comfort feeding (hand feeding)
meets the symbolic signiﬁcance of food, and re-establishes
the pleasure of sharing food and of the social interaction with
the caregiver.117 It is also effective for eliminating feelings of
hunger or thirst,118 and it may represent a valuable alterna-
tive to ANH.72 Comfort feeding offers a clear, goal-oriented
alternative to tube feeding and eliminates the troublesome
care/no care dichotomy imposed by current recommenda-
tions against ANH.
Conclusions and future directions
In the 50 years since Bernard Isaacs deﬁned the ‘geriatric gi-
ants’ of immobility, instability, incontinence, and impaired
intellect/memory, the understanding of those giants has
evolved to include four additional syndromes: frailty,
sarcopenia, the anorexia of ageing, and dementia.119 In the
current review, we hypothesized that cachexia represents
the ﬁnal common pathway of the four modern-day giants.
Cachexia and the failure to thrive commonly occur near the
end of life, and the failure to thrive is characterized by the pa-
tient’s inability to tolerate aggressive and inappropriate
treatments.
To date, investigations on cachexia and dementia are rela-
tively rare, and caution is advised in the interpretation of re-
sults that are merely extrapolated from cachexia associated
with other end-stage diseases.
Therefore, if cachexia represents a true symptom of de-
mentia or a side symptom is still an unsolved question.
It is conceivable to draw three different pathways that
might underpin the role of cachexia in dementia. First, it
could be hypothesized that cachexia represents the progres-
sion of brain neurodegeneration; the more amyloid burden
affects hypothalamus and the feeding regulation system,
the more cachexia develops as a side clinical effect.
Moreover, it could be considered a multifactorial origin for
cachexia in dementia, including the metabolic deregulation
(basal metabolism and energy expenditure) and the cognitive
and behavioural correlates as key determinant factors for the
onset and progression of the wasting syndrome, especially in
the later stages of dementia.
Not least, cachexia could be attributed as being a meta-
bolic disorder. Namely, a systemic increase of pro-
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inﬂammatory cytokines might promote IR as well as secreting
wasting tissue factors, ultimately responsible for the dysfunc-
tion in speciﬁc organs and the metabolic driven progression
of the wasting syndrome to cachexia, according to the natural
history of dementia.
To date, clinical interventions aimed at reversing cachexia
in advanced dementia have proven mostly ineffective, even
if largely unexplored.
Few efforts have been made to understand the pathophys-
iology of cachexia in dementia, and the current evidence to
this regard is insufﬁcient to ﬁll the knowledge gap.
Future research should aim to synthesize evidence from
the bench and the bedside to provide a useful pathophysio-
logical framework that supports a clinical decision-making
process towards the most precisely tailored interventions
for this vulnerable patient population.
Furthermore, prospective studies are needed to better de-
pict the trajectory of cachexia in dementia. Greater under-
standing of patient distress, prognoses, decision-making,
and family burden will allow the caregiving community to
identify the most effective strategies to improve end-of-life
care in patients with advanced dementia.
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Table A1. Effectiveness/complications of enteral nutrition

















1.31 ± 1.55 CG
vs. 2.74 ± 3.31
ENAspiration pneumonia:
58.1% vs. 25.0%







58% EN vs. 17%
CGDecubitus ulcers:
21% EN vs. 14%
CGRestraints:
71% EN vs. 56% CG
Increased weight




NA NA Median 175 days.
No increased survival
NA






NA Median 56 days NA
Teno
et al.91















GI bleeding > 5%, fever





in PS by Karnofsky.




or total lymphocyte count






4.3% NA No increased survival
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34.7% No improvement in functional
and nutritional status




Ticinesi et al.103 NA NA No increased survival EN









67% in NG, 44% in PEG.
NA NA NA





Arinzon et al.104 61% EN vs. 34% CG






No improvement in cognitive
and functional status.
NA NA
Jaul et al.105 NA No improvement in
nutritional status
or on healing pre-existing
pressure ulcers
Signiﬁcantly higher in EN groupNA
Rudberg et al.106 NA NA Survival at 1 year:





Takenoshita et al.94 Decreased pneumonia
and antibiotic use
NA EN group signiﬁcantly l




Takayama et al.95 NA NA EN group signiﬁcantly




reduced risk of death
BMI, body mass index; CG, control group in oral nutrition; EN, enteral nutrition by a feeding tube; GI, gastrointestinal bleeding; NA: not
available; NG, nasogastric tube; PEG, percutaneous endoscopic gastrostomy; PS, performance status; UTI, urinary tract infection.
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